K-One MM 2/.2 ml Inj. 2mg/0.2ml

Injection

Pack Size : 1 Injection x 1 Strip

Generics : Phytomenadione (Vitamin K1)

Manufacturer : Square Pharmaceuticals Ltd.

Best Price * TK 19.94

* Delivery will be done in Dhaka city only.

Alternative Product

More Information About - K-One MM 2/.2 ml Inj. 2mg/0.2ml

Description

Generic Name

Phytomenadione (Vitamin K1)

Precaution

Increased risk of severe haemolytic anaemia in neonates after large doses; severe hepatic impairment; pregnancy. Premature neonates weighing <2.5 kg. Lactation: Excreted in breast milk; use caution

Indication

Vitamin K deficiency, Over-anticoagulation, Vitamin K deficiency bleeding

Contra Indication

Hypersensitivity.

Dose

N/A

Side Effect

Anaphylaxis, dyspnoea, cyanosis, pain, swelling, phloebitis at the Inj site, diaphoresis, dizziness, hypotension (rare), allergic reactions after SC and IM inj.

Pregnancy Category

Name : Not Classified

Description

FDA has not yet classified the drug into a specified pregnancy category.

Mode of Action

Phytomenadione promotes hepatic synthesis of clotting factors. It is a naturally occurring compound that is used to prevent and treat haemorrhages related to vitamin K deficiency.

Interaction

Decreased effect of oral anticoagulants.

Pregnancy Category Note

Pregnancy The drug formulation contains benzyl alcohol, which has been associated with gasping syndrome in neonates; the preservative benzyl alcohol can cause serious adverse events and death when administered intravenously to neonates and infants; if therapy is needed during pregnancy, consider using a benzyl alcohol-free formulation; published studies with the use of phytonadione during pregnancy have not reported a clear association with phytonadione and adverse developmental outcomes; there are maternal and fetal risks associated with vitamin K deficiency during pregnancy; animal reproduction studies have not been conducted with phytonadione Pregnant women with vitamin K deficiency hypoprothrombinemia may be at an increased risk for bleeding diatheses during pregnancy and hemorrhagic events at delivery; subclinical maternal vitamin K deficiency during pregnancy has been implicated in rare cases of fetal intracranial hemorrhage Lactation The drug formulation contains benzyl alcohol; if available, a Preservative-Free formulation is recommended when therapy is needed during lactation; phytonadione is present in breastmilk; there are no data on effects of therapy on the breastfed child or on milk production; the developmental and health benefits of breastfeeding should be considered along with the clinical need for therapy and any potential adverse effects on breastfed child from the drug or from the underlying maternal condition

Adult Dose

Oral Vitamin K deficiency due to drugs or malabsorption Adult: 10-40 mg daily. Over-anticoagulation Adult: Up to 5 mg may be used. Dose depends on INR and degree of haemorrhage. Intravenous Over-anticoagulation Adult: 0.5-5 mg via slow IV inj. Dose depends on INR and degree of haemorrhage.

Child Dose

Intramuscular Prophylaxis of vitamin K deficiency bleeding in neonates Child: Neonate: 0.5-1 mg, given as a single dose via IM inj. Alternatively, 2 mg may be given orally, followed by a 2nd dose of 2 mg after 4-7 days. Parenteral Vitamin K deficiency bleeding in neonates Child: Infant: 1 mg by IV/IM/SC inj, further doses may be given if necessary

Renal Dose

N/A

Administration

May be taken with or without food.

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.